Details for Patent: 8,119,602

Which drugs does patent 8,119,602 protect, and when does it expire?

Patent 8,119,602 protects VICTRELIS and is included in one NDA.

This patent has eight patent family members in seven countries.

Summary for Patent: 8,119,602

Title:	Administration of HCV protease inhibitors in combination with food to improve bioavailability
Abstract:	Methods of treating, preventing or ameliorating one or more symptoms of hepatitis C in a subject comprising the step of administering at least one HCV protease inhibitor in combination with food are provided. Also provided are methods of increasing bioavailability of an HCV protease inhibitor and methods of increasing serum levels of an HCV protease inhibitor in a subject. All methods comprise adminstering at least one HCV protease inhibitor in combination with food, the at least one HCV protease inhibitor selected from the group consisting of compounds of Formulae I-XXVI, described herein. Administration of compounds of the present invention in combination with food provides improved bioavailability and increased peak serum levels of the compounds as compared to administration without food.
Inventor(s):	Jenny Zhang, Samir K. Gupta
Assignee:	Merck Sharp and Dohme LLC
Application Number:	US11/443,793
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,119,602

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Merck Sharp Dohme	VICTRELIS	boceprevir	CAPSULE;ORAL	202258-001	May 13, 2011		DISCN	No	No						TREATMENT OF CHRONIC HEPATITIS C (CHC) GENOTYPE 1 INFECTION, ADMINISTERED WITH FOOD

International Family Members for US Patent 8,119,602

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006252519
Canada	2610167
European Patent Office	1891089
New Zealand	563361
Poland	1891089
Taiwan	200716678
Taiwan	I380814